NEW YORK (GenomeWeb) – Arcis Biotechnology announced yesterday that it has signed a technology access agreement with Teleflex.
As part of the agreement, Teleflex will use Arcis' nucleic acid sample preparation chemistry to develop a rapid diagnostic assay using RNA detection. Arcis' two-step nucleic acid extraction and preservation technology enables earlier, more accurate diagnostic testing from a variety of sample types, the company said.
This partnership comes after Arcis' announcement earlier this month that it had raised £1.3 million ($1.7 million) in an investment round. The firm now plans to invest further in research and development, product development, and international business expansion.